Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myelomaPhase 1/2 ...
The study results also indicated that graft versus host disease status was associated with non-compliance following bone marrow transplantation.
The blood cancer expert comes to Sylvester Comprehensive Cancer Center after leading the discovery and testing of several immunotherapy approaches.
Encouraging data with RFS, OS, and NRM for Orca-T was also matched in a population of patients with hematologic cancers aged 55 years and older.
Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.